ArticleDigestive diseases and sciences2014
Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.
Article in Digestive diseases and sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.Gut microbes · 2019Trial
- Increased Autoimmunity Burden Is a Risk Factor for Developing Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Article
- Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment.Nature reviews. Gastroenterology & hepatology · 2026Review
- Beyond the "Master" Role in Allergy: Insights into Intestinal Mast Cell Plasticity and Gastrointestinal Diseases.Biomedicines · 2025Review
- Protection against DSS-induced colitis in mice through FcεRIα deficiency: the role of altered Lactobacillus.NPJ biofilms and microbiomes · 2024Article
- Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis.Clinical and experimental immunology · 2023Article
- Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Deep learning-based image analysis reveals significant differences in the number and distribution of mucosal CD3 and γδ T cells between Crohn's disease and ulcerative colitis.The journal of pathology. Clinical research · 2023Article
- Intestinal mucosal barrier in functional constipation: Dose it change?World journal of clinical cases · 2022Article
- Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome.Neurogastroenterology and motility · 2022Review
- Article
- Microinflammation in the intestinal mucosa and symptoms of irritable bowel syndrome.Journal of gastroenterology · 2022Article
- Resveratrol Treatment Prevents Increase of Mast Cells in Both Murine OVA Enteritis and IL-10International journal of molecular sciences · 2022Article
- Food Intolerance: The Role of Histamine.Nutrients · 2021Review
- A New Target Organ ofFrontiers in cellular and infection microbiology · 2021Article
- Review
- Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health.Inflammatory bowel diseases · 2020Article
- Irritable Bowel Syndrome and Neurological Deficiencies: Is There A Relationship? The Possible Relevance of the Oxidative Stress Status.Medicina (Kaunas, Lithuania) · 2020Review
- Potential neuro-immune therapeutic targets in irritable bowel syndrome.Therapeutic advances in gastroenterology · 2020Review
- The elusive case of human intraepithelial T cells in gut homeostasis and inflammation.Nature reviews. Gastroenterology & hepatology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMucosal immune activity may participate in irritable bowel syndrome (IBS) pathogenesis. Mast- and T cell numbers from patients with IBS or ulcerative colitis (UC) and healthy controls were determined.
methodsBetween November 2007 and May 2012, patients with diarrhea-predominant IBS (D-IBS, n = 83), 49 patients with UC, and 25 healthy controls were recruited. Of the UC group, 28 were in remission and 21 had mildly active UC. Biopsies from each colon segment were subjected to immunohistochemical analysis. The mast cells, intraepithelial lymphocytes (IELs), and lamina proprial lymphocytes (LPLs) were counted.
resultsCompared to the healthy controls, the patients with D-IBS, UC in remission, and mildly active UC had significantly higher mean colorectal mucosal mast-cell, IEL, and LPL counts. Comparison with the colon segments (ascending, transverse, descending, and sigmoid segments) that had once been involved in UC (in the patients with remission) revealed that the D-IBS colons had similar immune-cell counts. However, they had significantly fewer immune cells than the colon segments that presently showed involvement in the patients with mildly-activated UC. The mast-cell and IEL counts were similar in the D-IBS rectums and once-involved UC rectums but significantly higher in the presently-involved UC rectums. However, both the once-involved and presently-involved UC rectums had significantly higher LPL counts than the D-IBS rectums.
conclusionsPatients with D-IBS had significantly higher colonic mucosal immune-cell counts than healthy controls but had similar counts to patients with UC in remission. The symptoms in both conditions may originate from low-grade inflammation in the colonic mucosa.
Indexed as
Identifiers
24282051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.